Role of hepatectomy in gastric cancer with multiple liver-limited metastases
Sign Up to like & getrecommendations! Published in 2017 at "Gastric Cancer"
DOI: 10.1007/s10120-017-0730-9
Abstract: BackgroundSeveral studies have demonstrated the benefit of hepatectomy for treating gastric cancer (GC) with liver-limited metastases (LLM). The survival benefit of hepatectomy compared with that of systemic chemotherapy is unknown, particularly in patients with multiple… read more here.
Keywords: chemotherapy; gastric cancer; hepatectomy; limited metastases ... See more keywords
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of cancer"
DOI: 10.1016/j.ejca.2016.10.028
Abstract: Secondary resection is a chance of cure for a subgroup of metastatic colorectal cancer (mCRC) patients with unresectable liver-limited disease. Medical treatment has a dual goal: to induce tumour shrinkage and to prevent disease relapse.… read more here.
Keywords: metastatic colorectal; colorectal cancer; folfoxiri plus; liver limited ... See more keywords
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-67676-1
Abstract: Hepatic resection is the gold standard treatment for patients affected by liver-limited colorectal metastases. Reports addressing the impact of multidisciplinary team (MDT) evaluation on survival are controversial. The aim of this study was to evaluate… read more here.
Keywords: mdt; hepatic resection; management; mdt cohort ... See more keywords
Role of cetuximab in conversion therapy in advanced KRAS WT colorectal cancer with liver limited disease: A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.4_suppl.748
Abstract: 748Background: Majority of advanced colorectal cancer (CRC) patients with liver limited disease (LLD) that undergo curative partial liver resection relapse within 5 years. Peri-operative chemotherapy is currently utilized, however the benefit of this is modest… read more here.
Keywords: chemotherapy; colorectal cancer; cetuximab; advanced kras ... See more keywords
A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.734
Abstract: 734Background: It is still a topic of ongoing debate as to which of the two agents, anti-VEGF antibody or anti-EGFR antibody, is more effective in patients with KRAS Exon 2 or RAS wild-type metastatic colorectal… read more here.
Keywords: metastatic colorectal; mfolfox6; mfolfox6 plus; colorectal cancer ... See more keywords